NASDAQ:TTOO - T2 Biosystems Stock Price, Price Target & More

$6.95 -0.02 (-0.29 %)
(As of 04/23/2018 04:00 PM ET)
Previous Close$6.97
Today's Range$6.85 - $7.02
52-Week Range$2.50 - $7.53
Volume114,814 shs
Average Volume304,807 shs
Market Capitalization$251.06 million
P/E Ratio-3.31
Dividend YieldN/A
Beta1.19

About T2 Biosystems (NASDAQ:TTOO)

T2 Biosystems logoT2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States. It provides T2 Magnetic Resonance platform that enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, and urine. The company also offers T2Dx, a bench-top instrument for sepsis, Lyme disease, and other applications, as well as T2Candida panel for the detection of candida species in human whole blood specimens. In addition, it is developing T2Bacteria, a multiplex diagnostic panel that detects various bacterial pathogens associated with sepsis; T2Lyme for the detection of various strains of Lyme disease-causing bacteria; and T2Plex, an integrated instrument for hemostasis applications, as well as T2HemoStat panel, a panel of diagnostic tests that can provide data across the hemostasis spectrum, including measurements of fibrinogen, platelet activity, and clot lysis. The company has collaboration agreement with Canon U.S. Life Sciences, Inc. to develop a novel diagnostic test panel to detect Lyme disease, a tick-borne illness; and Allergan Sales, LLC for the direct detection diagnostic test panel that adds additional bacteria species to the existing T2Bacteria product candidate and testing drug resistance directly in whole blood. T2 Biosystems, Inc. was founded in 2006 and is headquartered in Lexington, Massachusetts.

Receive TTOO News and Ratings via Email

Sign-up to receive the latest news and ratings for TTOO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:TTOO
CUSIPN/A
Phone781-761-4646

Debt

Debt-to-Equity Ratio1.29%
Current Ratio0.86%
Quick Ratio0.83%

Price-To-Earnings

Trailing P/E Ratio-3.31
Forward P/E Ratio-3.76
P/E GrowthN/A

Sales & Book Value

Annual Sales$4.66 million
Price / Sales53.72
Cash FlowN/A
Price / CashN/A
Book Value$0.04 per share
Price / Book173.75

Profitability

EPS (Most Recent Fiscal Year)($2.10)
Net Income$-62,420,000.00
Net Margins-1,335.51%
Return on Equity-432.00%
Return on Assets-94.62%

Miscellaneous

Employees161
Outstanding Shares36,020,000

How to Become a New Pot Stock Millionaire

T2 Biosystems (NASDAQ:TTOO) Frequently Asked Questions

What is T2 Biosystems' stock symbol?

T2 Biosystems trades on the NASDAQ under the ticker symbol "TTOO."

How were T2 Biosystems' earnings last quarter?

T2 Biosystems (NASDAQ:TTOO) posted its earnings results on Thursday, November, 2nd. The medical equipment provider reported ($0.45) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.49) by $0.04. The medical equipment provider earned $1.11 million during the quarter, compared to the consensus estimate of $1.10 million. T2 Biosystems had a negative return on equity of 432.00% and a negative net margin of 1,335.51%. T2 Biosystems's revenue was up 2.8% compared to the same quarter last year. View T2 Biosystems' Earnings History.

What price target have analysts set for TTOO?

5 analysts have issued twelve-month price targets for T2 Biosystems' stock. Their forecasts range from $4.00 to $8.50. On average, they expect T2 Biosystems' share price to reach $5.94 in the next twelve months. View Analyst Ratings for T2 Biosystems.

Who are some of T2 Biosystems' key competitors?

Who are T2 Biosystems' key executives?

T2 Biosystems' management team includes the folowing people:
  • Mr. John P. McDonough, CEO, Pres & Director (Age 58)
  • Prof. Michael J. Cima Ph.D., Co-Founder, Director and Member of Scientific Advisory Board (Age 58)
  • Dr. Thomas J. Lowery Jr., Ph.D., Chief Scientific Officer (Age 39)
  • Mr. Lee Josephson Ph.D., Co-Founder and Member of Scientific Advisory Board
  • Mr. John M. Sprague, CFO & Sr. VP (Age 59)

Has T2 Biosystems been receiving favorable news coverage?

Media coverage about TTOO stock has trended somewhat positive this week, Accern reports. Accern scores the sentiment of media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. T2 Biosystems earned a news sentiment score of 0.09 on Accern's scale. They also assigned headlines about the medical equipment provider an impact score of 46.55 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

How do I buy shares of T2 Biosystems?

Shares of TTOO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is T2 Biosystems' stock price today?

One share of TTOO stock can currently be purchased for approximately $6.95.

How big of a company is T2 Biosystems?

T2 Biosystems has a market capitalization of $251.06 million and generates $4.66 million in revenue each year. The medical equipment provider earns $-62,420,000.00 in net income (profit) each year or ($2.10) on an earnings per share basis. T2 Biosystems employs 161 workers across the globe.

How can I contact T2 Biosystems?

T2 Biosystems' mailing address is 101 HARTWELL AVENUE, LEXINGTON MA, 02421. The medical equipment provider can be reached via phone at 781-761-4646 or via email at [email protected]


MarketBeat Community Rating for T2 Biosystems (TTOO)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  195 (Vote Outperform)
Underperform Votes:  167 (Vote Underperform)
Total Votes:  362
MarketBeat's community ratings are surveys of what our community members think about T2 Biosystems and other stocks. Vote "Outperform" if you believe TTOO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TTOO will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

T2 Biosystems (NASDAQ:TTOO) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
5 Wall Street analysts have issued ratings and price targets for T2 Biosystems in the last 12 months. Their average twelve-month price target is $5.94, suggesting that the stock has a possible downside of 14.53%. The high price target for TTOO is $8.50 and the low price target for TTOO is $4.00. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyHold
Consensus Rating Score: 2.602.602.502.43
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $5.94$5.84$6.8333$7.00
Price Target Upside: 14.53% downside5.65% downside79.82% upside66.27% upside

T2 Biosystems (NASDAQ:TTOO) Consensus Price Target History

Price Target History for T2 Biosystems (NASDAQ:TTOO)

T2 Biosystems (NASDAQ:TTOO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/29/2018HC WainwrightBoost Price TargetBuy -> Buy$8.00 -> $8.50LowView Rating Details
1/29/2018Goldman SachsInitiated CoverageNeutral -> Neutral$5.20HighView Rating Details
10/30/2017Canaccord GenuityReiterated RatingBuy$6.00N/AView Rating Details
5/8/2017BTIG ResearchUpgradeSell -> Neutral$4.00HighView Rating Details
5/3/2017Cantor FitzgeraldLower Price TargetOverweight$7.00 -> $6.00HighView Rating Details
3/14/2017Morgan StanleyDowngradeEqual Weight -> Underweight$5.00HighView Rating Details
2/5/2017WBB SecuritiesReiterated RatingBuy$12.00N/AView Rating Details
11/10/2016Leerink SwannReiterated RatingMarket Perform$5.00N/AView Rating Details
7/9/2016Janney Montgomery ScottReiterated RatingHoldN/AView Rating Details
(Data available from 4/23/2016 forward)

Earnings

T2 Biosystems (NASDAQ:TTOO) Earnings History and Estimates Chart

Earnings by Quarter for T2 Biosystems (NASDAQ:TTOO)

T2 Biosystems (NASDAQ:TTOO) Earnings Estimates

2018 EPS Consensus Estimate: ($1.37)
2019 EPS Consensus Estimate: ($1.25)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.35)($0.35)($0.35)
Q2 20181($0.34)($0.34)($0.34)
Q3 20181($0.34)($0.34)($0.34)
Q4 20181($0.34)($0.34)($0.34)
Q1 20191($0.31)($0.31)($0.31)
Q2 20191($0.31)($0.31)($0.31)
Q3 20191($0.31)($0.31)($0.31)
Q4 20191($0.32)($0.32)($0.32)

T2 Biosystems (NASDAQ TTOO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/2/2017Q3 2017($0.49)($0.45)$1.10 million$1.11 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.49)($0.50)$0.79 million$0.96 millionViewListenView Earnings Details
5/2/2017Q1 2017($0.47)($0.48)$1.55 million$0.94 millionViewListenView Earnings Details
2/16/2017Q4 2016($0.45)($0.47)$1.23 million$0.91 millionViewN/AView Earnings Details
11/1/2016Q3($0.52)($0.51)$2.03 million$1.08 millionViewN/AView Earnings Details
8/1/2016Q2($0.56)($0.58)$1.53 million$0.99 millionViewN/AView Earnings Details
5/2/2016Q1($0.54)($0.55)$1.01 million$1.10 millionViewN/AView Earnings Details
2/16/2016Q4($0.59)($0.56)$1.21 million$1.01 millionViewListenView Earnings Details
11/2/2015Q3($0.59)($0.57)$0.66 million$1.05 millionViewN/AView Earnings Details
8/4/2015Q215($0.57)($0.54)$0.34 million$0.56 millionViewN/AView Earnings Details
5/5/2015Q115($0.57)($0.53)$0.22 million$0.19 millionViewN/AView Earnings Details
2/17/2015Q414($0.44)($0.45)$0.12 millionViewN/AView Earnings Details
11/4/2014Q314($0.58)($0.71)$0.10 millionViewN/AView Earnings Details
9/19/2014Q2 2014($6.35)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

T2 Biosystems (NASDAQ:TTOO) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

T2 Biosystems (NASDAQ TTOO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 38.70%
Institutional Ownership Percentage: 52.33%
Insider Trading History for T2 Biosystems (NASDAQ:TTOO)
Institutional Ownership by Quarter for T2 Biosystems (NASDAQ:TTOO)

T2 Biosystems (NASDAQ TTOO) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/16/2017David B ElsbreeDirectorBuy1,500$4.11$6,165.00View SEC Filing  
6/6/2017Darlene M Deptula-HicksCFOBuy4,000$3.58$14,320.004,000View SEC Filing  
6/6/2017David B ElsbreeDirectorBuy10,000$3.50$35,000.0050,000View SEC Filing  
6/6/2017Joanne SpadoroCOOBuy5,000$3.50$17,500.00View SEC Filing  
6/6/2017Michael Terrence GibbsGeneral CounselBuy1,000$3.51$3,510.00View SEC Filing  
3/15/2017David B ElsbreeDirectorBuy10,000$5.97$59,700.0040,000View SEC Filing  
6/30/2016Rahul DhandaSVPSell3,589$8.16$29,286.243,589View SEC Filing  
3/16/2016Rahul DhandaSVPSell7,588$8.01$60,779.884,647View SEC Filing  
12/9/2015Aisling Capital Iii LpMajor ShareholderBuy307,692$9.75$2,999,997.00View SEC Filing  
12/9/2015David B ElsbreeDirectorBuy10,000$9.75$97,500.0030,000View SEC Filing  
7/24/2015Polaris Venture Partners V, L.Major ShareholderSell15,399$15.04$231,600.96View SEC Filing  
7/22/2015Polaris Venture Partners V, L.Major ShareholderSell14,999$15.22$228,284.78View SEC Filing  
7/21/2015Polaris Venture Partners V, L.Major ShareholderSell14,999$15.42$231,284.58View SEC Filing  
7/20/2015Polaris Venture Partners V, L.Major ShareholderSell14,999$16.05$240,733.95View SEC Filing  
7/17/2015Polaris Venture Partners V, L.Major ShareholderSell44,997$16.26$731,651.22View SEC Filing  
7/14/2015Polaris Venture Partners V, L.Major ShareholderSell29,998$16.57$497,066.86View SEC Filing  
7/10/2015Polaris Venture Partners V, L.Major ShareholderSell44,997$16.25$731,201.25View SEC Filing  
7/10/2015Thomas J LoweryInsiderSell2,000$16.03$32,060.00View SEC Filing  
7/7/2015Polaris Venture Partners V, L.Major ShareholderSell44,997$15.91$715,902.27View SEC Filing  
7/1/2015Polaris Venture Partners V, L.Major ShareholderSell44,997$16.09$724,001.73View SEC Filing  
6/30/2015Polaris Venture Partners V, L.Major ShareholderSell14,999$16.22$243,283.78View SEC Filing  
6/29/2015Polaris Venture Partners V, L.Major ShareholderSell14,999$16.28$244,183.72View SEC Filing  
6/26/2015Polaris Venture Partners V, L.Major ShareholderSell44,997$17.08$768,548.76View SEC Filing  
6/23/2015Polaris Venture Partners V, L.Major ShareholderSell29,998$18.18$545,363.64View SEC Filing  
6/22/2015Polaris Venture Partners V, L.Major ShareholderSell14,999$18.22$273,281.78View SEC Filing  
6/18/2015Thomas J LoweryInsiderSell1,000$18.65$18,650.00View SEC Filing  
6/12/2015Michael J CimaDirectorBuy1,000$18.91$18,910.00View SEC Filing  
6/12/2015Thomas J LoweryInsiderSell1,471$18.55$27,287.05View SEC Filing  
5/8/2015Michael A PfallerInsiderSell15,440$16.31$251,826.40View SEC Filing  
4/20/2015Thomas J LoweryInsiderSell1,000$18.43$18,430.00View SEC Filing  
3/4/2015David B ElsbreeDirectorBuy1,450$15.05$21,822.50View SEC Filing  
11/13/2014David B ElsbreeDirectorBuy1,500$14.75$22,125.00View SEC Filing  
8/12/2014Aisling Capital Iii LpMajor ShareholderBuy454,545$11.00$4,999,995.00View SEC Filing  
8/12/2014Sarah O KalilCOOBuy15,000$11.00$165,000.00View SEC Filing  
8/12/2014Thomas J CarellaDirectorBuy909,090$11.00$9,999,990.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

T2 Biosystems (NASDAQ TTOO) News Headlines

Source:
DateHeadline
T2 Biosystems (TTOO) Lowered to "Sell" at ValuEngineT2 Biosystems (TTOO) Lowered to "Sell" at ValuEngine
www.americanbankingnews.com - April 18 at 10:41 AM
T2 Biosystems (TTOO) Given Average Rating of "Hold" by AnalystsT2 Biosystems (TTOO) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - April 18 at 3:36 AM
Zacks: Analysts Anticipate T2 Biosystems (TTOO) Will Announce Quarterly Sales of $1.38 MillionZacks: Analysts Anticipate T2 Biosystems (TTOO) Will Announce Quarterly Sales of $1.38 Million
www.americanbankingnews.com - April 16 at 4:57 AM
-$0.39 Earnings Per Share Expected for T2 Biosystems (TTOO) This Quarter-$0.39 Earnings Per Share Expected for T2 Biosystems (TTOO) This Quarter
www.americanbankingnews.com - April 14 at 1:09 AM
ValuEngine Upgrades T2 Biosystems (TTOO) to "Hold"ValuEngine Upgrades T2 Biosystems (TTOO) to "Hold"
www.americanbankingnews.com - April 12 at 10:47 AM
T2 Biosystems (TTOO) Coverage Initiated at HC WainwrightT2 Biosystems (TTOO) Coverage Initiated at HC Wainwright
www.americanbankingnews.com - April 6 at 4:17 PM
T2 Biosystems Reports Granting of Inducement AwardsT2 Biosystems Reports Granting of Inducement Awards
finance.yahoo.com - April 4 at 4:17 PM
T2 Biosystems (TTOO) Rating Reiterated by Canaccord GenuityT2 Biosystems (TTOO) Rating Reiterated by Canaccord Genuity
www.americanbankingnews.com - April 4 at 12:34 AM
T2 Biosystems (TTOO) Rating Lowered to Hold at Zacks Investment ResearchT2 Biosystems (TTOO) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - April 3 at 3:34 PM
T2 Biosystems (TTOO) Upgraded to Buy at Zacks Investment ResearchT2 Biosystems (TTOO) Upgraded to Buy at Zacks Investment Research
www.americanbankingnews.com - April 1 at 7:24 AM
$1.40 Million in Sales Expected for T2 Biosystems Inc (TTOO) This Quarter$1.40 Million in Sales Expected for T2 Biosystems Inc (TTOO) This Quarter
www.americanbankingnews.com - March 30 at 4:19 AM
T2 Biosystems (TTOO) Rating Increased to Buy at Zacks Investment ResearchT2 Biosystems (TTOO) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - March 29 at 3:01 PM
HC Wainwright Increases T2 Biosystems (TTOO) Price Target to $8.50HC Wainwright Increases T2 Biosystems (TTOO) Price Target to $8.50
www.americanbankingnews.com - March 29 at 9:19 AM
Multiple New Studies Demonstrate T2 Biosystems’ Diagnostics Improve Detection of Sepsis Causing Pathogens Over Blood Culture-based DiagnosticsMultiple New Studies Demonstrate T2 Biosystems’ Diagnostics Improve Detection of Sepsis Causing Pathogens Over Blood Culture-based Diagnostics
finance.yahoo.com - March 28 at 5:22 PM
Zacks: Brokerages Anticipate T2 Biosystems Inc (TTOO) to Announce -$0.42 EPSZacks: Brokerages Anticipate T2 Biosystems Inc (TTOO) to Announce -$0.42 EPS
www.americanbankingnews.com - March 28 at 3:13 AM
T2 Biosystems Inc (TTOO) Given Consensus Rating of "Hold" by AnalystsT2 Biosystems Inc (TTOO) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - March 24 at 3:36 AM
T2 Biosystems (TTOO) Cut to Hold at Zacks Investment ResearchT2 Biosystems (TTOO) Cut to Hold at Zacks Investment Research
www.americanbankingnews.com - March 23 at 10:08 AM
T2 Biosystems to Present at the 17th Annual Needham Healthcare ... - NasdaqT2 Biosystems to Present at the 17th Annual Needham Healthcare ... - Nasdaq
www.nasdaq.com - March 21 at 8:42 AM
T2 Biosystems to Present at the 17th Annual Needham Healthcare ... - GlobeNewswire (press release)T2 Biosystems to Present at the 17th Annual Needham Healthcare ... - GlobeNewswire (press release)
globenewswire.com - March 20 at 8:22 AM
T2 Biosystems (TTOO) Raised to Sell at ValuEngineT2 Biosystems (TTOO) Raised to Sell at ValuEngine
www.americanbankingnews.com - March 19 at 11:16 PM
T2 Biosystems to Present at the 17th Annual Needham Healthcare ConferenceT2 Biosystems to Present at the 17th Annual Needham Healthcare Conference
finance.yahoo.com - March 19 at 5:21 PM
T2 Biosystems (TTOO) Upgraded to Sell by ValuEngineT2 Biosystems (TTOO) Upgraded to Sell by ValuEngine
www.americanbankingnews.com - March 18 at 7:42 PM
Edited Transcript of TTOO earnings conference call or presentation 6-Mar-18 9:30pm GMTEdited Transcript of TTOO earnings conference call or presentation 6-Mar-18 9:30pm GMT
finance.yahoo.com - March 18 at 8:13 AM
Critical Analysis: Cardiovascular Systems (CSII) versus T2 Biosystems (TTOO)Critical Analysis: Cardiovascular Systems (CSII) versus T2 Biosystems (TTOO)
www.americanbankingnews.com - March 16 at 7:24 PM
Zacks: Analysts Anticipate T2 Biosystems Inc (TTOO) Will Post Quarterly Sales of $1.40 MillionZacks: Analysts Anticipate T2 Biosystems Inc (TTOO) Will Post Quarterly Sales of $1.40 Million
www.americanbankingnews.com - March 12 at 2:38 AM
-$0.42 Earnings Per Share Expected for T2 Biosystems Inc (TTOO) This Quarter-$0.42 Earnings Per Share Expected for T2 Biosystems Inc (TTOO) This Quarter
www.americanbankingnews.com - March 10 at 9:20 PM
T2 Biosystems Inc to Post Q1 2018 Earnings of ($0.35) Per Share, Leerink Swann Forecasts (TTOO)T2 Biosystems Inc to Post Q1 2018 Earnings of ($0.35) Per Share, Leerink Swann Forecasts (TTOO)
www.americanbankingnews.com - March 9 at 8:52 AM
Equities Analysts Issue Forecasts for T2 Biosystems Incs Q1 2019 Earnings (TTOO)Equities Analysts Issue Forecasts for T2 Biosystems Inc's Q1 2019 Earnings (TTOO)
www.americanbankingnews.com - March 8 at 11:50 AM
HC Wainwright Reiterates "$8.00" Price Target for T2 Biosystems (TTOO)HC Wainwright Reiterates "$8.00" Price Target for T2 Biosystems (TTOO)
www.americanbankingnews.com - March 7 at 10:16 PM
T2 Biosystems (TTOO) CEO John McDonough on Q4 2017 Results - Earnings Call Transcript - Seeking AlphaT2 Biosystems' (TTOO) CEO John McDonough on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 7 at 6:39 PM
T2 Biosystems Reports Granting of Inducement Award - GlobeNewswire (press release)T2 Biosystems Reports Granting of Inducement Award - GlobeNewswire (press release)
globenewswire.com - March 7 at 8:13 AM
T2 Biosystems Reports Granting of Inducement AwardT2 Biosystems Reports Granting of Inducement Award
finance.yahoo.com - March 7 at 8:13 AM
Should T2 Biosystems Inc’s (NASDAQ:TTOO) Recent Earnings Decline Worry You?Should T2 Biosystems Inc’s (NASDAQ:TTOO) Recent Earnings Decline Worry You?
finance.yahoo.com - March 6 at 5:43 PM
T2 Biosystems Reports Fourth Quarter and Full-Year 2017 Financial Results and Business UpdateT2 Biosystems Reports Fourth Quarter and Full-Year 2017 Financial Results and Business Update
finance.yahoo.com - March 6 at 5:43 PM
T2 Biosystems (TTOO) Secures Max $2M Grant from CARB-X to Support Development of New Tests for Drug-Resistant ... - StreetInsider.comT2 Biosystems (TTOO) Secures Max $2M Grant from CARB-X to Support Development of New Tests for Drug-Resistant ... - StreetInsider.com
www.streetinsider.com - March 6 at 8:12 AM
T2 Biosystems Awarded Up To $2 Million by CARB-X to Support Development of New Tests on the T2Dx Instrument for Drug-Resistant BacteriaT2 Biosystems Awarded Up To $2 Million by CARB-X to Support Development of New Tests on the T2Dx Instrument for Drug-Resistant Bacteria
finance.yahoo.com - March 6 at 8:12 AM
42 Biggest Movers From Friday - Benzinga42 Biggest Movers From Friday - Benzinga
www.benzinga.com - March 5 at 8:14 AM
T2 Biosystems (TTOO) Set to Announce Earnings on TuesdayT2 Biosystems (TTOO) Set to Announce Earnings on Tuesday
www.americanbankingnews.com - March 2 at 8:10 PM
T2 Biosystems Inc (TTOO) Stake Lowered by Fuller & Thaler Asset Management Inc.T2 Biosystems Inc (TTOO) Stake Lowered by Fuller & Thaler Asset Management Inc.
www.americanbankingnews.com - March 1 at 11:14 AM
Contrasting T2 Biosystems (TTOO) & Neogen (NEOG)Contrasting T2 Biosystems (TTOO) & Neogen (NEOG)
www.americanbankingnews.com - March 1 at 5:12 AM
T2 Biosystems Inc (TTOO) Receives Consensus Rating of "Hold" from AnalystsT2 Biosystems Inc (TTOO) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - February 27 at 3:40 AM
T2 Biosystems Inc (TTOO) Expected to Announce Quarterly Sales of $1.20 MillionT2 Biosystems Inc (TTOO) Expected to Announce Quarterly Sales of $1.20 Million
www.americanbankingnews.com - February 24 at 10:54 AM
T2 Biosystems Announces 2017 Fourth Quarter and Full-Year Financial and Operational Results Release and Conference Call DateT2 Biosystems Announces 2017 Fourth Quarter and Full-Year Financial and Operational Results Release and Conference Call Date
finance.yahoo.com - February 20 at 8:13 AM
T2 Biosystems (TTOO) PT Set at $8.00 by HC WainwrightT2 Biosystems (TTOO) PT Set at $8.00 by HC Wainwright
www.americanbankingnews.com - February 12 at 6:34 PM
Two New Studies Demonstrate T2Candida’s Advantages over Current Diagnostic TestingTwo New Studies Demonstrate T2Candida’s Advantages over Current Diagnostic Testing
finance.yahoo.com - February 9 at 9:32 AM
 Analysts Anticipate T2 Biosystems Inc (TTOO) Will Post Quarterly Sales of $1.20 Million Analysts Anticipate T2 Biosystems Inc (TTOO) Will Post Quarterly Sales of $1.20 Million
www.americanbankingnews.com - February 7 at 12:01 PM
T2 Biosystems Announces CFO TransitionT2 Biosystems Announces CFO Transition
finance.yahoo.com - February 6 at 9:07 AM
T2 Biosystems to Present at the 7th Annual Leerink Partners Global Healthcare ConferenceT2 Biosystems to Present at the 7th Annual Leerink Partners Global Healthcare Conference
finance.yahoo.com - February 6 at 9:07 AM
T2 Biosystems (TTOO) Set to Announce Earnings on MondayT2 Biosystems (TTOO) Set to Announce Earnings on Monday
www.americanbankingnews.com - February 5 at 4:00 AM
 Brokerages Expect T2 Biosystems Inc (TTOO) Will Post Earnings of -$0.42 Per Share Brokerages Expect T2 Biosystems Inc (TTOO) Will Post Earnings of -$0.42 Per Share
www.americanbankingnews.com - February 5 at 3:12 AM

SEC Filings

T2 Biosystems (NASDAQ:TTOO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

T2 Biosystems (NASDAQ:TTOO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

T2 Biosystems (NASDAQ TTOO) Stock Chart for Monday, April, 23, 2018

Loading chart…

This page was last updated on 4/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.